spacer
home > epc > summer 2002 > global edc adoption
PUBLICATIONS
European Pharmaceutical Contractor

Global EDC Adoption

Internet electronic data capture (EDC) is now established as an effective way of conducting clinical trials. Faster access to cleaner data, a more streamlined and less batch-based process and faster database lock are driving real benefits for trial sponsors, leading to a growing acceptance that EDC can be a better way of running studies.

With regions such as South America and Asia Pacific rapidly developing as areas for clinical trials based on the growing importance of these markets to pharma companies, and the adoption of international standards for conducting clinical research, are EDC studies a realistic option for global studies? In fact, online Internet EDC actually facilitates running studies across a number of geographically dispersed countries.

The unique capability to remotely access and centrally manage data as it rapidly accumulates from sites around the world removes the delays and costs inherent in the traditional labour-intensive paper shipping processes. As Internet use spreads rapidly throughout the world, the barriers to deploying EDC are quickly disappearing, making this an increasingly attractive approach for sponsors. There are now many examples of successful EDC trials running beyond the traditional areas of the US and Europe, including sites in Eastern Europe, Africa, Asia Pacific and China.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mark Wren, Director of eService and Support, and Martin Young, Professional Services Director for Phase Forward

Mark Wren brings to Phase Forward over 15 years' experience of successfully implementing technology to the drug development process from both a sponsor and a vendor perspective. Prior to joining Phase Forward, Mark was Director of Clinical Trial Services at Dendrite International where he successfully implemented e-clinical trials systems for many of the large pharmaceutical companies. He has also held managerial positions at the Celltech Group and British Biotech.

Martin Young is Professional Services Director for Phase Forward, responsible for international consulting services and major technology transfer clients. Since establishing Phase Forward's international operations in 1999, Martin has been involved in building the international business and, following the Clinsoft acquisition in 2001, integrating both companies' operations outside North America. Over the past 18 years, Martin has undertaken a number of commercial, IT and re-engineering roles within the IT and pharmaceutical industries. Prior to joining Phase Forward, he worked for Glaxo Wellcome, leading internal and external ventures focused on improving the development process. Martin has a degree in Engineering Science and an Executive MBA.

spacer
Mark Wren
spacer
spacer
spacer
Martin Young
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement